The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …

Objectives To describe the safety of vaccines against SARS-CoV-2 in people with
inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Introduction To assess the incidence and risk factors for breakthrough COVID-19 infection in
a vaccinated cohort of patients with autoimmune rheumatic diseases (AIRDs) and determine …

Objective While COVID-19 vaccination prevents severe infections, poor immunogenicity in
immunocompromised people threatens vaccine effectiveness. We analysed the clinical …

Objective Rheumatic disease patients on certain immunomodulators are at increased risk of
impaired humoral response to SARS-CoV-2 vaccines. We aimed to identify factors …

Objective To describe disease-modifying antirheumatic drug (DMARD) disruption, rheumatic
disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 …

Background Rheumatoid arthritis has been associated with severe COVID-19, but few
studies have investigated how phenotypes of rheumatoid arthritis affect these associations …

Beyond the acute illness caused by severe acute respiratory coronavirus 2 (SARS-CoV-2)
infection, about one-fifth of infections result in long-term persistence of symptoms despite the …